EUVIMEDEUVIMED entdecken
Crossref

VEGFA Stop-Gained Variant Deteriorates Cardiac Remodeling in Myocardial Infarction

Zhongxiang Chen iD, Diqi Zhu, Kaa Seng Lai, Yiwei Chen, Yuqing Hu iD, Yabo Fang, Zihang Yan, Beibei Hu iD, Zhen Zhang iD, Min Zhang iD, Fen Li iD

Circulation: Genomic and Precision Medicine · 2025-08 · 18 (4)

DOI: 10.1161/circgen.124.004879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Genomic and Precision Medicine, 2025-08. Verfasst von Zhongxiang Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Cardiology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, China (Z.C., D.Z., Y.C., Y.H…. Hauptthemen laut MEDLINE: Myocardial Infarction, Vascular Endothelial Growth Factor A, Ventricular Remodeling. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A sustained dosage of VEGFA (vascular endothelial growth factor A) is crucial for angiogenesis in both homeostasis and cardiovascular diseases. Start codon CUG-initiated alternative translation is a conserved mechanism for producing mature VEGFA. Genetic surveys have identified stop-gained variants predicted to prematurely terminate CUG-initiated translation without affecting start codon ATG-initiated translation. However, the impacts of these variants on the vasculature in steady-state and disease conditions remain unknown. METHODS: Using CRISPR/Cas9 genome editing, we established the Vegfa Q150X/Q150 allele (Q150X), a mouse genetic model that mimics the human VEGFA stop-gained variant. The effects of this variant were tested in both adult homeostatic conditions and the acute myocardial infarction (MI) model. We analyzed and quantified cardiac vasculature structure using immunofluorescence and light-sheet imaging. Furthermore, we characterized cellular heterogeneity, cell-cell interactions, and gene regulation using single-nucleus RNA sequencing, as well as cell type-specific transcriptomics and epigenomics. RESULTS: Homozygous mice carrying the stop-gained variant were viable. VEGFA dosage was reduced to 70% in the Q150X homeostatic heart, with no significant alteration in cardiac function or vasculature. In the MI model, VEGFA dosage in Q150X was reduced to about 40% within the first week post-infarction, leading to functional deterioration in the post-MI hearts. Significant changes in cellular composition were observed 3 days post-MI. In particular, endothelial cells in Q150X diverged into a state that showed a higher level of hypoxia stress, an elevated inflammatory response, and increased extracellular matrix secretion. In addition, we observed an increase in Nppb + stressed cardiomyocytes in both 3 days post-MI and homeostasis. Finally, proinflammatory macrophages, neutrophils, and Cd8 + T cells were enriched in the ischemic zone of Q150X hearts. CONCLUSIONS: CUG-initiated translation contributes significantly to the production of mature VEGFA in ischemic hearts. VEGFA dosage is critical in determining the cellular microenvironment during ischemic injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionVascular Endothelial Growth Factor AVentricular RemodelingAnimalsMiceHumansDisease Models, AnimalMaleCRISPR-Cas Systems

Stichwörter der Autor:innen

angiogenesisendothelial cellshypoxiamyocardial infarctionvascular endothelial growth factor A

Substanzen

Vascular Endothelial Growth Factor Avascular endothelial growth factor A, mouse

Autor:innen und Institutionen

  • Department of Pediatric Cardiology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, China (Z.C., D.Z., Y.C., Y.H., Z.Y., F.L.).
  • Pediatric Translational Medicine Institute and Pediatric Congenital Heart Disease Institute, Shanghai Children' s Medical Center, Shanghai Jiaotong University School of Medicine, China (K.S.L., Y.F., B.H., Z.Z., M.Z.).
  • Shanghai Collaborative Innovative Centre of Intelligent Medical Device and Active Health, Shanghai University of Medicine and Health Sciences, China (Z.Z.).
  • Core Research Laboratory, Fujian Children's Hospital, China (Z.Z.).
  • Department of Hainan Key Laboratory of Molecular Medicine for Women and Children' s Health, Shanghai Children' s Medical Center Hainan Branch, Shanghai Jiao Tong University School of Medicine, Sanya, China (Z.Z.).

ORCID-Profile: Zhongxiang Chen, Yuqing Hu, Beibei Hu, Zhen Zhang, Min Zhang, Fen Li

Zitieren

APA

Chen, Z., Zhu, D., Lai, K. S., Chen, Y., Hu, Y., Fang, Y., Yan, Z., Hu, B., Zhang, Z., Zhang, M., & Li, F. (2025). VEGFA Stop-Gained Variant Deteriorates Cardiac Remodeling in Myocardial Infarction. Circulation: Genomic and Precision Medicine, 18(4). https://doi.org/10.1161/circgen.124.004879

Vancouver

Chen Z, Zhu D, Lai KS, Chen Y, Hu Y, Fang Y, et al. VEGFA Stop-Gained Variant Deteriorates Cardiac Remodeling in Myocardial Infarction. Circulation: Genomic and Precision Medicine. 2025;18(4). doi:10.1161/circgen.124.004879

BibTeX
@article{Chen2025,
  author = {Chen, Zhongxiang and Zhu, Diqi and Lai, Kaa Seng and Chen, Yiwei and Hu, Yuqing and Fang, Yabo and Yan, Zihang and Hu, Beibei and Zhang, Zhen and Zhang, Min and Li, Fen},
  title = {VEGFA Stop-Gained Variant Deteriorates Cardiac Remodeling in Myocardial Infarction},
  journal = {Circulation: Genomic and Precision Medicine},
  year = {2025},
  volume = {18},
  number = {4},
  doi = {10.1161/circgen.124.004879}
}
Kostenlos starten →